CA2642828A1 - Affinity regions - Google Patents

Info

Publication number

CA2642828A1

CA2642828A1 CA002642828A CA2642828A CA2642828A1 CA 2642828 A1 CA2642828 A1 CA 2642828A1 CA 002642828 A CA002642828 A CA 002642828A CA 2642828 A CA2642828 A CA 2642828A CA 2642828 A1 CA2642828 A1 CA 2642828A1

Authority

CA

Canada

Prior art keywords

protein

cross

igiv

beta

misfolded

Prior art date

2006-02-16

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 108090000623 proteins and genes Proteins 0.000 claims abstract description 859
• 102000004169 proteins and genes Human genes 0.000 claims abstract description 858
• 238000000034 method Methods 0.000 claims abstract description 134
• 230000027455 binding Effects 0.000 claims description 267
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 159
• 201000010099 disease Diseases 0.000 claims description 150
• 239000000203 mixture Substances 0.000 claims description 144
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 85
• 150000001875 compounds Chemical class 0.000 claims description 70
• 239000000523 sample Substances 0.000 claims description 59
• 238000002360 preparation method Methods 0.000 claims description 55
• 230000000694 effects Effects 0.000 claims description 49
• 210000004027 cell Anatomy 0.000 claims description 47
• 238000011282 treatment Methods 0.000 claims description 35
• 210000001772 blood platelet Anatomy 0.000 claims description 33
• 239000003814 drug Substances 0.000 claims description 33
• 239000008194 pharmaceutical composition Substances 0.000 claims description 31
• 239000008280 blood Substances 0.000 claims description 30
• 238000012360 testing method Methods 0.000 claims description 30
• 210000004369 blood Anatomy 0.000 claims description 28
• 230000001965 increasing effect Effects 0.000 claims description 28
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 26
• 208000032843 Hemorrhage Diseases 0.000 claims description 25
• 208000034158 bleeding Diseases 0.000 claims description 25
• 230000000740 bleeding effect Effects 0.000 claims description 25
• 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 25
• 239000012636 effector Substances 0.000 claims description 24
• 206010002022 amyloidosis Diseases 0.000 claims description 23
• 206010040047 Sepsis Diseases 0.000 claims description 19
• 206010061218 Inflammation Diseases 0.000 claims description 16
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
• 239000012530 fluid Substances 0.000 claims description 16
• 230000004054 inflammatory process Effects 0.000 claims description 16
• 239000012460 protein solution Substances 0.000 claims description 16
• 230000002708 enhancing effect Effects 0.000 claims description 15
• 230000002401 inhibitory effect Effects 0.000 claims description 15
• 244000052769 pathogen Species 0.000 claims description 15
• 206010003246 arthritis Diseases 0.000 claims description 14
• 239000000470 constituent Substances 0.000 claims description 14
• 239000007787 solid Substances 0.000 claims description 14
• 239000007864 aqueous solution Substances 0.000 claims description 13
• 230000000295 complement effect Effects 0.000 claims description 13
• 230000001939 inductive effect Effects 0.000 claims description 13
• 230000001717 pathogenic effect Effects 0.000 claims description 13
• 201000001320 Atherosclerosis Diseases 0.000 claims description 12
• 208000007536 Thrombosis Diseases 0.000 claims description 12
• 210000001124 body fluid Anatomy 0.000 claims description 12
• 239000010839 body fluid Substances 0.000 claims description 12
• 206010057249 Phagocytosis Diseases 0.000 claims description 11
• 230000015271 coagulation Effects 0.000 claims description 11
• 238000005345 coagulation Methods 0.000 claims description 11
• 238000000502 dialysis Methods 0.000 claims description 11
• 239000003112 inhibitor Substances 0.000 claims description 11
• 201000006417 multiple sclerosis Diseases 0.000 claims description 11
• 210000001539 phagocyte Anatomy 0.000 claims description 11
• 230000008782 phagocytosis Effects 0.000 claims description 11
• 102000004127 Cytokines Human genes 0.000 claims description 10
• 108090000695 Cytokines Proteins 0.000 claims description 10
• 230000000813 microbial effect Effects 0.000 claims description 10
• 244000045947 parasite Species 0.000 claims description 10
• 230000036961 partial effect Effects 0.000 claims description 10
• 239000000126 substance Substances 0.000 claims description 10
• 208000023761 AL amyloidosis Diseases 0.000 claims description 9
• 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 claims description 9
• 208000036142 Viral infection Diseases 0.000 claims description 9
• 230000001580 bacterial effect Effects 0.000 claims description 9
• 206010012601 diabetes mellitus Diseases 0.000 claims description 9
• 230000001404 mediated effect Effects 0.000 claims description 9
• 230000009385 viral infection Effects 0.000 claims description 9
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 8
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 8
• 230000003247 decreasing effect Effects 0.000 claims description 8
• 230000002265 prevention Effects 0.000 claims description 8
• 210000001179 synovial fluid Anatomy 0.000 claims description 8
• 208000023275 Autoimmune disease Diseases 0.000 claims description 7
• 238000009007 Diagnostic Kit Methods 0.000 claims description 7
• 208000015294 blood coagulation disease Diseases 0.000 claims description 7
• 238000004519 manufacturing process Methods 0.000 claims description 7
• 230000003571 opsonizing effect Effects 0.000 claims description 7
• 230000017854 proteolysis Effects 0.000 claims description 7
• 238000011160 research Methods 0.000 claims description 7
• 208000018737 Parkinson disease Diseases 0.000 claims description 6
• 208000024777 Prion disease Diseases 0.000 claims description 6
• 238000009825 accumulation Methods 0.000 claims description 6
• 230000003467 diminishing effect Effects 0.000 claims description 6
• 230000001537 neural effect Effects 0.000 claims description 6
• 239000000047 product Substances 0.000 claims description 6
• 239000013074 reference sample Substances 0.000 claims description 6
• 208000004639 AIDS-Related Opportunistic Infections Diseases 0.000 claims description 5
• 208000000044 Amnesia Diseases 0.000 claims description 5
• 208000014644 Brain disease Diseases 0.000 claims description 5
• 208000032274 Encephalopathy Diseases 0.000 claims description 5
• 206010028980 Neoplasm Diseases 0.000 claims description 5
• 108091005804 Peptidases Proteins 0.000 claims description 5
• 239000004365 Protease Substances 0.000 claims description 5
• 230000003213 activating effect Effects 0.000 claims description 5
• 201000011510 cancer Diseases 0.000 claims description 5
• 206010015037 epilepsy Diseases 0.000 claims description 5
• 235000013305 food Nutrition 0.000 claims description 5
• 208000027866 inflammatory disease Diseases 0.000 claims description 5
• 230000003993 interaction Effects 0.000 claims description 5
• 231100000863 loss of memory Toxicity 0.000 claims description 5
• 238000000926 separation method Methods 0.000 claims description 5
• 108050001049 Extracellular proteins Proteins 0.000 claims description 4
• 239000006143 cell culture medium Substances 0.000 claims description 4
• 239000003085 diluting agent Substances 0.000 claims description 4
• 230000002434 immunopotentiative effect Effects 0.000 claims description 4
• 239000007790 solid phase Substances 0.000 claims description 4
• 108020005087 unfolded proteins Proteins 0.000 claims description 4
• 229960005486 vaccine Drugs 0.000 claims description 4
• 238000012800 visualization Methods 0.000 claims description 4
• 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
• 230000002452 interceptive effect Effects 0.000 claims description 3
• 230000014207 opsonization Effects 0.000 claims description 3
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
• 239000010836 blood and blood product Substances 0.000 claims description 2
• 229940125691 blood product Drugs 0.000 claims description 2
• 239000002537 cosmetic Substances 0.000 claims description 2
• 239000003599 detergent Substances 0.000 claims description 2
• 235000015872 dietary supplement Nutrition 0.000 claims description 2
• 210000004880 lymph fluid Anatomy 0.000 claims description 2
• 208000030852 Parasitic disease Diseases 0.000 claims 5
• 230000036281 parasite infection Effects 0.000 claims 5
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
• 235000018102 proteins Nutrition 0.000 description 750
• 239000011159 matrix material Substances 0.000 description 128
• 241000282414 Homo sapiens Species 0.000 description 87
• 108010059886 Apolipoprotein A-I Proteins 0.000 description 79
• 102000005666 Apolipoprotein A-I Human genes 0.000 description 79
• 229920002684 Sepharose Polymers 0.000 description 79
• JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 68
• 229940027941 immunoglobulin g Drugs 0.000 description 61
• 229940013982 octagam Drugs 0.000 description 58
• 108010055267 advanced glycation end products-bovine serum albumin Proteins 0.000 description 57
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 56
• IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 53
• 239000002953 phosphate buffered saline Substances 0.000 description 53
• 239000000872 buffer Substances 0.000 description 52
• 239000000243 solution Substances 0.000 description 47
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
• 108060003951 Immunoglobulin Proteins 0.000 description 37
• 102000018358 immunoglobulin Human genes 0.000 description 37
• 241000699670 Mus sp. Species 0.000 description 36
• 238000002965 ELISA Methods 0.000 description 34
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 34
• 241000699666 Mus <mouse, genus> Species 0.000 description 33
• 108010073385 Fibrin Proteins 0.000 description 32
• 102000009123 Fibrin Human genes 0.000 description 32
• 229950003499 fibrin Drugs 0.000 description 32
• 238000003556 assay Methods 0.000 description 30
• 230000015572 biosynthetic process Effects 0.000 description 30
• 238000002474 experimental method Methods 0.000 description 29
• 230000004913 activation Effects 0.000 description 28
• 239000011780 sodium chloride Substances 0.000 description 28
• 239000002158 endotoxin Substances 0.000 description 26
• 229940009600 gammagard Drugs 0.000 description 26
• 102000004196 processed proteins & peptides Human genes 0.000 description 26
• 229940072221 immunoglobulins Drugs 0.000 description 24
• 238000011534 incubation Methods 0.000 description 24
• 239000000463 material Substances 0.000 description 24
• 108010071584 oxidized low density lipoprotein Proteins 0.000 description 24
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 23
• 108010007622 LDL Lipoproteins Proteins 0.000 description 23
• 102000007330 LDL Lipoproteins Human genes 0.000 description 23
• 102000013566 Plasminogen Human genes 0.000 description 23
• 108010051456 Plasminogen Proteins 0.000 description 23
• 238000004458 analytical method Methods 0.000 description 22
• 210000002381 plasma Anatomy 0.000 description 22
• 208000024827 Alzheimer disease Diseases 0.000 description 21
• 230000037361 pathway Effects 0.000 description 21
• 239000000975 dye Substances 0.000 description 19
• 101000693922 Bos taurus Albumin Proteins 0.000 description 18
• 229920006008 lipopolysaccharide Polymers 0.000 description 18
• 108010043026 HGF activator Proteins 0.000 description 17
• 102100031465 Hepatocyte growth factor activator Human genes 0.000 description 17
• 238000007254 oxidation reaction Methods 0.000 description 17
• 108091005996 glycated proteins Proteins 0.000 description 16
• 238000001727 in vivo Methods 0.000 description 16
• 238000002823 phage display Methods 0.000 description 16
• 238000005259 measurement Methods 0.000 description 15
• 230000003647 oxidation Effects 0.000 description 15
• 108010058846 Ovalbumin Proteins 0.000 description 14
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
• 239000002253 acid Substances 0.000 description 14
• 230000002776 aggregation Effects 0.000 description 14
• 238000004220 aggregation Methods 0.000 description 14
• 239000000427 antigen Substances 0.000 description 14
• 239000013641 positive control Substances 0.000 description 14
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 13
• 239000007995 HEPES buffer Substances 0.000 description 13
• 229920001213 Polysorbate 20 Polymers 0.000 description 13
• 230000009286 beneficial effect Effects 0.000 description 13
• 238000010790 dilution Methods 0.000 description 13
• 239000012895 dilution Substances 0.000 description 13
• 229940092253 ovalbumin Drugs 0.000 description 13
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 13
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 13
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 12
• 239000011324 bead Substances 0.000 description 12
• 239000002243 precursor Substances 0.000 description 12
• 239000011550 stock solution Substances 0.000 description 12
• 230000001225 therapeutic effect Effects 0.000 description 12
• 102100037362 Fibronectin Human genes 0.000 description 11
• 108010067306 Fibronectins Proteins 0.000 description 11
• 241001465754 Metazoa Species 0.000 description 11
• 241000700159 Rattus Species 0.000 description 11
• 230000033885 plasminogen activation Effects 0.000 description 11
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
• 241001529936 Murinae Species 0.000 description 10
• 210000003719 b-lymphocyte Anatomy 0.000 description 10
• 230000005802 health problem Effects 0.000 description 10
• 210000004408 hybridoma Anatomy 0.000 description 10
• 239000003446 ligand Substances 0.000 description 10
• 208000007153 proteostasis deficiencies Diseases 0.000 description 10
• 210000002966 serum Anatomy 0.000 description 10
• 239000007858 starting material Substances 0.000 description 10
• 239000006228 supernatant Substances 0.000 description 10
• 238000005406 washing Methods 0.000 description 10
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
• 206010002023 Amyloidoses Diseases 0.000 description 9
• 241000282412 Homo Species 0.000 description 9
• 238000002835 absorbance Methods 0.000 description 9
• 108091007433 antigens Proteins 0.000 description 9
• 102000036639 antigens Human genes 0.000 description 9
• 230000004154 complement system Effects 0.000 description 9
• 230000007423 decrease Effects 0.000 description 9
• 230000036425 denaturation Effects 0.000 description 9
• 238000004925 denaturation Methods 0.000 description 9
• 208000035475 disorder Diseases 0.000 description 9
• 230000005284 excitation Effects 0.000 description 9
• -1 fibrils Substances 0.000 description 9
• 102000009027 Albumins Human genes 0.000 description 8
• 108010088751 Albumins Proteins 0.000 description 8
• 108010035532 Collagen Proteins 0.000 description 8
• 102000008186 Collagen Human genes 0.000 description 8
• 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 8
• 108010079505 Endostatins Proteins 0.000 description 8
• 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 description 8
• 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 description 8
• 239000012190 activator Substances 0.000 description 8
• 230000002411 adverse Effects 0.000 description 8
• 238000006243 chemical reaction Methods 0.000 description 8
• 229920001436 collagen Polymers 0.000 description 8
• 229940012952 fibrinogen Drugs 0.000 description 8
• 238000000338 in vitro Methods 0.000 description 8
• 230000006698 induction Effects 0.000 description 8
• 239000002609 medium Substances 0.000 description 8
• 102000005962 receptors Human genes 0.000 description 8
• 108020003175 receptors Proteins 0.000 description 8
• 238000002560 therapeutic procedure Methods 0.000 description 8
• 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 7
• 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 7
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 7
• 108010049003 Fibrinogen Proteins 0.000 description 7
• 102000008946 Fibrinogen Human genes 0.000 description 7
• 230000000712 assembly Effects 0.000 description 7
• 238000000429 assembly Methods 0.000 description 7
• 239000012148 binding buffer Substances 0.000 description 7
• ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 7
• 229910000366 copper(II) sulfate Inorganic materials 0.000 description 7
• 238000010168 coupling process Methods 0.000 description 7
• 238000005859 coupling reaction Methods 0.000 description 7
• 238000001514 detection method Methods 0.000 description 7
• 229940079593 drug Drugs 0.000 description 7
• 230000036252 glycation Effects 0.000 description 7
• 238000010438 heat treatment Methods 0.000 description 7
• 230000001976 improved effect Effects 0.000 description 7
• 208000015181 infectious disease Diseases 0.000 description 7
• 230000002757 inflammatory effect Effects 0.000 description 7
• 230000003389 potentiating effect Effects 0.000 description 7
• 241000894007 species Species 0.000 description 7
• 210000001519 tissue Anatomy 0.000 description 7
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
• 108020004414 DNA Proteins 0.000 description 6
• 108010080865 Factor XII Proteins 0.000 description 6
• 102000000429 Factor XII Human genes 0.000 description 6
• 108010088842 Fibrinolysin Proteins 0.000 description 6
• 108010022999 Serine Proteases Proteins 0.000 description 6
• 102000012479 Serine Proteases Human genes 0.000 description 6
• 238000003917 TEM image Methods 0.000 description 6
• 235000001014 amino acid Nutrition 0.000 description 6
• 230000000903 blocking effect Effects 0.000 description 6
• 239000003153 chemical reaction reagent Substances 0.000 description 6
• 239000003795 chemical substances by application Substances 0.000 description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
• 230000008878 coupling Effects 0.000 description 6
• 238000011161 development Methods 0.000 description 6
• 230000018109 developmental process Effects 0.000 description 6
• 230000020764 fibrinolysis Effects 0.000 description 6
• 230000028993 immune response Effects 0.000 description 6
• 230000003053 immunization Effects 0.000 description 6
• 238000002649 immunization Methods 0.000 description 6
• 230000005764 inhibitory process Effects 0.000 description 6
• 239000013642 negative control Substances 0.000 description 6
• 230000007170 pathology Effects 0.000 description 6
• 102000013415 peroxidase activity proteins Human genes 0.000 description 6
• 108040007629 peroxidase activity proteins Proteins 0.000 description 6
• 229920001184 polypeptide Polymers 0.000 description 6
• 230000002035 prolonged effect Effects 0.000 description 6
• 230000002829 reductive effect Effects 0.000 description 6
• 230000004044 response Effects 0.000 description 6
• 238000004627 transmission electron microscopy Methods 0.000 description 6
• 239000013598 vector Substances 0.000 description 6
• KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 5
• 208000035143 Bacterial infection Diseases 0.000 description 5
• 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 5
• 239000004471 Glycine Substances 0.000 description 5
• 241000124008 Mammalia Species 0.000 description 5
• 102000005431 Molecular Chaperones Human genes 0.000 description 5
• 108010006519 Molecular Chaperones Proteins 0.000 description 5
• 241000283973 Oryctolagus cuniculus Species 0.000 description 5
• 108700028909 Serum Amyloid A Proteins 0.000 description 5
• 102000054727 Serum Amyloid A Human genes 0.000 description 5
• 239000007983 Tris buffer Substances 0.000 description 5
• 150000001413 amino acids Chemical group 0.000 description 5
• 208000022362 bacterial infectious disease Diseases 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 230000023555 blood coagulation Effects 0.000 description 5
• 230000015556 catabolic process Effects 0.000 description 5
• 238000003271 compound fluorescence assay Methods 0.000 description 5
• 210000004443 dendritic cell Anatomy 0.000 description 5
• 210000002889 endothelial cell Anatomy 0.000 description 5
• 239000000835 fiber Substances 0.000 description 5
• 239000007850 fluorescent dye Substances 0.000 description 5
• 239000011521 glass Substances 0.000 description 5
• 239000001963 growth medium Substances 0.000 description 5
• BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 5
• 229910000359 iron(II) sulfate Inorganic materials 0.000 description 5
• 210000000629 knee joint Anatomy 0.000 description 5
• 230000033001 locomotion Effects 0.000 description 5
• 229940012957 plasmin Drugs 0.000 description 5
• 238000000746 purification Methods 0.000 description 5
• 238000010561 standard procedure Methods 0.000 description 5
• 239000000725 suspension Substances 0.000 description 5
• 208000024891 symptom Diseases 0.000 description 5
• 231100000331 toxic Toxicity 0.000 description 5
• 230000002588 toxic effect Effects 0.000 description 5
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
• 239000003656 tris buffered saline Substances 0.000 description 5
• 239000011534 wash buffer Substances 0.000 description 5
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
• 101100028789 Arabidopsis thaliana PBS1 gene Proteins 0.000 description 4
• 241000894006 Bacteria Species 0.000 description 4
• 241000283707 Capra Species 0.000 description 4
• 102000014914 Carrier Proteins Human genes 0.000 description 4
• 101710184994 Complement control protein Proteins 0.000 description 4
• 102000051325 Glucagon Human genes 0.000 description 4
• 108060003199 Glucagon Proteins 0.000 description 4
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
• 108091006905 Human Serum Albumin Proteins 0.000 description 4
• 102000008100 Human Serum Albumin Human genes 0.000 description 4
• 208000023105 Huntington disease Diseases 0.000 description 4
• 108010058683 Immobilized Proteins Proteins 0.000 description 4
• 239000012480 LAL reagent Substances 0.000 description 4
• 102000016943 Muramidase Human genes 0.000 description 4
• 108010014251 Muramidase Proteins 0.000 description 4
• 102000047918 Myelin Basic Human genes 0.000 description 4
• 101710107068 Myelin basic protein Proteins 0.000 description 4
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 4
• 108700021638 Neuro-Oncological Ventral Antigen Proteins 0.000 description 4
• 102000035195 Peptidases Human genes 0.000 description 4
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
• 239000012980 RPMI-1640 medium Substances 0.000 description 4
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
• 239000002671 adjuvant Substances 0.000 description 4
• 229960002684 aminocaproic acid Drugs 0.000 description 4
• 108091008324 binding proteins Proteins 0.000 description 4
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
• 210000004534 cecum Anatomy 0.000 description 4
• 238000004113 cell culture Methods 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• 238000005119 centrifugation Methods 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 239000011248 coating agent Substances 0.000 description 4
• 238000000576 coating method Methods 0.000 description 4
• 239000012228 culture supernatant Substances 0.000 description 4
• 230000001419 dependent effect Effects 0.000 description 4
• 238000013461 design Methods 0.000 description 4
• 230000003292 diminished effect Effects 0.000 description 4
• 208000009190 disseminated intravascular coagulation Diseases 0.000 description 4
• 238000009826 distribution Methods 0.000 description 4
• 230000004064 dysfunction Effects 0.000 description 4
• 238000010828 elution Methods 0.000 description 4
• 239000012149 elution buffer Substances 0.000 description 4
• 201000002491 encephalomyelitis Diseases 0.000 description 4
• 238000005516 engineering process Methods 0.000 description 4
• 230000004927 fusion Effects 0.000 description 4
• 229960004666 glucagon Drugs 0.000 description 4
• MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 4
• 238000003505 heat denaturation Methods 0.000 description 4
• 229960002897 heparin Drugs 0.000 description 4
• 229920000669 heparin Polymers 0.000 description 4
• 210000000987 immune system Anatomy 0.000 description 4
• 230000005847 immunogenicity Effects 0.000 description 4
• 230000028709 inflammatory response Effects 0.000 description 4
• 229960000274 lysozyme Drugs 0.000 description 4
• 239000004325 lysozyme Substances 0.000 description 4
• 235000010335 lysozyme Nutrition 0.000 description 4
• 210000002540 macrophage Anatomy 0.000 description 4
• 238000010172 mouse model Methods 0.000 description 4
• 230000035772 mutation Effects 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 230000000069 prophylactic effect Effects 0.000 description 4
• 102200158871 rs33955330 Human genes 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 210000000952 spleen Anatomy 0.000 description 4
• 230000009885 systemic effect Effects 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• 208000030507 AIDS Diseases 0.000 description 3
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
• 239000005995 Aluminium silicate Substances 0.000 description 3
• 244000303258 Annona diversifolia Species 0.000 description 3
• 235000002198 Annona diversifolia Nutrition 0.000 description 3
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
• 108010045374 CD36 Antigens Proteins 0.000 description 3
• 102000053028 CD36 Antigens Human genes 0.000 description 3
• 102000000844 Cell Surface Receptors Human genes 0.000 description 3
• 108010001857 Cell Surface Receptors Proteins 0.000 description 3
• 206010010099 Combined immunodeficiency Diseases 0.000 description 3
• 229920002307 Dextran Polymers 0.000 description 3
• 206010061818 Disease progression Diseases 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 241000588724 Escherichia coli Species 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 108010029144 Factor IIa Proteins 0.000 description 3
• 241000287828 Gallus gallus Species 0.000 description 3
• 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 108010004889 Heat-Shock Proteins Proteins 0.000 description 3
• 102000002812 Heat-Shock Proteins Human genes 0.000 description 3
• 101710172064 Low-density lipoprotein receptor-related protein Proteins 0.000 description 3
• 208000001388 Opportunistic Infections Diseases 0.000 description 3
• 108091000054 Prion Proteins 0.000 description 3
• 108010045517 Serum Amyloid P-Component Proteins 0.000 description 3
• 102100036202 Serum amyloid P-component Human genes 0.000 description 3
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
• 241000700605 Viruses Species 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 238000013019 agitation Methods 0.000 description 3
• 235000012211 aluminium silicate Nutrition 0.000 description 3
• 235000012538 ammonium bicarbonate Nutrition 0.000 description 3
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 3
• 229940098773 bovine serum albumin Drugs 0.000 description 3
• 210000004556 brain Anatomy 0.000 description 3
• 239000007975 buffered saline Substances 0.000 description 3
• 229910052799 carbon Inorganic materials 0.000 description 3
• 210000002421 cell wall Anatomy 0.000 description 3
• 238000010367 cloning Methods 0.000 description 3
• 230000035602 clotting Effects 0.000 description 3
• 230000024203 complement activation Effects 0.000 description 3
• 239000002299 complementary DNA Substances 0.000 description 3
• 210000004292 cytoskeleton Anatomy 0.000 description 3
• 230000034994 death Effects 0.000 description 3
• 231100000517 death Toxicity 0.000 description 3
• 238000002050 diffraction method Methods 0.000 description 3
• VWLWTJHKQHRTNC-UHFFFAOYSA-L dipotassium;8-anilino-5-(4-anilino-5-sulfonatonaphthalen-1-yl)naphthalene-1-sulfonate Chemical compound [K+].[K+].C=12C(S(=O)(=O)[O-])=CC=CC2=C(C=2C3=CC=CC(=C3C(NC=3C=CC=CC=3)=CC=2)S([O-])(=O)=O)C=CC=1NC1=CC=CC=C1 VWLWTJHKQHRTNC-UHFFFAOYSA-L 0.000 description 3
• 230000005750 disease progression Effects 0.000 description 3
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
• 239000012153 distilled water Substances 0.000 description 3
• 229940088598 enzyme Drugs 0.000 description 3
• 239000000208 fibrin degradation product Substances 0.000 description 3
• 230000006870 function Effects 0.000 description 3
• 230000001771 impaired effect Effects 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 238000002955 isolation Methods 0.000 description 3
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
• 210000003292 kidney cell Anatomy 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 238000012544 monitoring process Methods 0.000 description 3
• 238000006386 neutralization reaction Methods 0.000 description 3
• 239000003960 organic solvent Substances 0.000 description 3
• 239000002245 particle Substances 0.000 description 3
• 239000008188 pellet Substances 0.000 description 3
• 229920000642 polymer Polymers 0.000 description 3
• 239000003642 reactive oxygen metabolite Substances 0.000 description 3
• 238000011084 recovery Methods 0.000 description 3
• 102000014452 scavenger receptors Human genes 0.000 description 3
• 108010078070 scavenger receptors Proteins 0.000 description 3
• 238000012216 screening Methods 0.000 description 3
• 238000010187 selection method Methods 0.000 description 3
• 208000002491 severe combined immunodeficiency Diseases 0.000 description 3
• 238000010186 staining Methods 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 229910021653 sulphate ion Inorganic materials 0.000 description 3
• FHZSIZRTNHGLSX-FLMSMKGQSA-N (2s)-1-[(2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-oxobutanoyl]pyrrolidine-2-carboxyl Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=CC=C1 FHZSIZRTNHGLSX-FLMSMKGQSA-N 0.000 description 2
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
• BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 2
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
• QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
• SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 2
• 208000009304 Acute Kidney Injury Diseases 0.000 description 2
• 208000037259 Amyloid Plaque Diseases 0.000 description 2
• 208000033399 Anaphylactic responses Diseases 0.000 description 2
• 102000006991 Apolipoprotein B-100 Human genes 0.000 description 2
• 108010008150 Apolipoprotein B-100 Proteins 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 108010074051 C-Reactive Protein Proteins 0.000 description 2
• 102100032752 C-reactive protein Human genes 0.000 description 2
• 238000011740 C57BL/6 mouse Methods 0.000 description 2
• 102100032887 Clusterin Human genes 0.000 description 2
• 108090000197 Clusterin Proteins 0.000 description 2
• 102000000989 Complement System Proteins Human genes 0.000 description 2
• 108010069112 Complement System Proteins Proteins 0.000 description 2
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
• 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 108010000912 Egg Proteins Proteins 0.000 description 2
• 102000002322 Egg Proteins Human genes 0.000 description 2
• 101000962643 Escherichia coli (strain K12) Malate synthase A Proteins 0.000 description 2
• 208000009386 Experimental Arthritis Diseases 0.000 description 2
• 108010087819 Fc receptors Proteins 0.000 description 2
• 102000009109 Fc receptors Human genes 0.000 description 2
• 241000233866 Fungi Species 0.000 description 2
• 102000014702 Haptoglobin Human genes 0.000 description 2
• 108050005077 Haptoglobin Proteins 0.000 description 2
• 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 2
• 101500028775 Homo sapiens Glucagon Proteins 0.000 description 2
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
• 208000019758 Hypergammaglobulinemia Diseases 0.000 description 2
• 102000000589 Interleukin-1 Human genes 0.000 description 2
• 108010002352 Interleukin-1 Proteins 0.000 description 2
• 102000004889 Interleukin-6 Human genes 0.000 description 2
• 108090001005 Interleukin-6 Proteins 0.000 description 2
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
• 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 2
• 102100023302 Myelin-oligodendrocyte glycoprotein Human genes 0.000 description 2
• 206010028851 Necrosis Diseases 0.000 description 2
• PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
• 108091028043 Nucleic acid sequence Proteins 0.000 description 2
• 102000015636 Oligopeptides Human genes 0.000 description 2
• 108010038807 Oligopeptides Proteins 0.000 description 2
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 208000007452 Plasmacytoma Diseases 0.000 description 2
• 108010093965 Polymyxin B Proteins 0.000 description 2
• 102000029797 Prion Human genes 0.000 description 2
• 206010036790 Productive cough Diseases 0.000 description 2
• 101001076287 Rattus norvegicus Insulin-like growth factor II Proteins 0.000 description 2
• 208000033626 Renal failure acute Diseases 0.000 description 2
• 238000012300 Sequence Analysis Methods 0.000 description 2
• 241000194017 Streptococcus Species 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
• 108090000190 Thrombin Proteins 0.000 description 2
• 102000003790 Thrombin receptors Human genes 0.000 description 2
• 108010000499 Thromboplastin Proteins 0.000 description 2
• 102000002262 Thromboplastin Human genes 0.000 description 2
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• 201000011040 acute kidney failure Diseases 0.000 description 2
• 208000012998 acute renal failure Diseases 0.000 description 2
• 238000001261 affinity purification Methods 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 2
• DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
• 230000036783 anaphylactic response Effects 0.000 description 2
• 210000000612 antigen-presenting cell Anatomy 0.000 description 2
• 230000001640 apoptogenic effect Effects 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 210000001367 artery Anatomy 0.000 description 2
• 239000012131 assay buffer Substances 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 238000013357 binding ELISA Methods 0.000 description 2
• 210000000988 bone and bone Anatomy 0.000 description 2
• 239000007853 buffer solution Substances 0.000 description 2
• 230000020411 cell activation Effects 0.000 description 2
• 230000007541 cellular toxicity Effects 0.000 description 2
• 229940096384 chicken egg white lysozyme Drugs 0.000 description 2
• 238000003776 cleavage reaction Methods 0.000 description 2
• 238000004891 communication Methods 0.000 description 2
• 239000013078 crystal Substances 0.000 description 2
• 238000012258 culturing Methods 0.000 description 2
• 230000009089 cytolysis Effects 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 208000033679 diabetic kidney disease Diseases 0.000 description 2
• 238000003745 diagnosis Methods 0.000 description 2
• ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 2
• 229910000397 disodium phosphate Inorganic materials 0.000 description 2
• 235000019800 disodium phosphate Nutrition 0.000 description 2
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
• 235000014103 egg white Nutrition 0.000 description 2
• 210000003743 erythrocyte Anatomy 0.000 description 2
• 239000013604 expression vector Substances 0.000 description 2
• 239000012894 fetal calf serum Substances 0.000 description 2
• 230000003480 fibrinolytic effect Effects 0.000 description 2
• 239000012634 fragment Substances 0.000 description 2
• 108020001507 fusion proteins Proteins 0.000 description 2
• 102000037865 fusion proteins Human genes 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• RKGLLHCSSVJTAN-YYICOITRSA-N glucagen Chemical compound Cl.C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 RKGLLHCSSVJTAN-YYICOITRSA-N 0.000 description 2
• 229940095886 glucagen Drugs 0.000 description 2
• 229960001031 glucose Drugs 0.000 description 2
• 108010004903 glycosylated serum albumin Proteins 0.000 description 2
• 229940106780 human fibrinogen Drugs 0.000 description 2
• 208000010544 human prion disease Diseases 0.000 description 2
• 230000002209 hydrophobic effect Effects 0.000 description 2
• 230000036039 immunity Effects 0.000 description 2
• 230000002163 immunogen Effects 0.000 description 2
• 230000002055 immunohistochemical effect Effects 0.000 description 2
• 238000011065 in-situ storage Methods 0.000 description 2
• 229940100601 interleukin-6 Drugs 0.000 description 2
• 229940008228 intravenous immunoglobulins Drugs 0.000 description 2
• 150000002500 ions Chemical class 0.000 description 2
• 239000004816 latex Substances 0.000 description 2
• 229920000126 latex Polymers 0.000 description 2
• 210000002414 leg Anatomy 0.000 description 2
• 210000003141 lower extremity Anatomy 0.000 description 2
• 235000018977 lysine Nutrition 0.000 description 2
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• 210000004962 mammalian cell Anatomy 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
• 102000026412 misfolded protein binding proteins Human genes 0.000 description 2
• 108091014761 misfolded protein binding proteins Proteins 0.000 description 2
• 210000001616 monocyte Anatomy 0.000 description 2
• 239000000178 monomer Substances 0.000 description 2
• 230000017074 necrotic cell death Effects 0.000 description 2
• 150000007523 nucleic acids Chemical group 0.000 description 2
• 230000008506 pathogenesis Effects 0.000 description 2
• 239000012071 phase Substances 0.000 description 2
• 230000035790 physiological processes and functions Effects 0.000 description 2
• 230000010118 platelet activation Effects 0.000 description 2
• 210000004623 platelet-rich plasma Anatomy 0.000 description 2
• 229920000024 polymyxin B Polymers 0.000 description 2
• 229960005266 polymyxin b Drugs 0.000 description 2
• 239000001103 potassium chloride Substances 0.000 description 2
• 235000011164 potassium chloride Nutrition 0.000 description 2
• GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
• 208000022256 primary systemic amyloidosis Diseases 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 229920006395 saturated elastomer Polymers 0.000 description 2
• 230000007017 scission Effects 0.000 description 2
• 235000017557 sodium bicarbonate Nutrition 0.000 description 2
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
• 239000001488 sodium phosphate Substances 0.000 description 2
• 229910000162 sodium phosphate Inorganic materials 0.000 description 2
• 235000011008 sodium phosphates Nutrition 0.000 description 2
• 238000009987 spinning Methods 0.000 description 2
• 210000003802 sputum Anatomy 0.000 description 2
• 208000024794 sputum Diseases 0.000 description 2
• 230000000087 stabilizing effect Effects 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• 235000011149 sulphuric acid Nutrition 0.000 description 2
• 230000002459 sustained effect Effects 0.000 description 2
• 230000008961 swelling Effects 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 229960004072 thrombin Drugs 0.000 description 2
• 108010093640 thrombin receptor peptide SFLLRNP Proteins 0.000 description 2
• 230000000451 tissue damage Effects 0.000 description 2
• 231100000827 tissue damage Toxicity 0.000 description 2
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
• 210000003606 umbilical vein Anatomy 0.000 description 2
• 210000002700 urine Anatomy 0.000 description 2
• 238000003260 vortexing Methods 0.000 description 2
• HAGOWCONESKMDW-FRSCJGFNSA-N (2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC1=CC=CC=C1 HAGOWCONESKMDW-FRSCJGFNSA-N 0.000 description 1
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
• TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
• GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
• YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
• 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 1
• FWEOQOXTVHGIFQ-UHFFFAOYSA-N 8-anilinonaphthalene-1-sulfonic acid Chemical compound C=12C(S(=O)(=O)O)=CC=CC2=CC=CC=1NC1=CC=CC=C1 FWEOQOXTVHGIFQ-UHFFFAOYSA-N 0.000 description 1
• ITZMJCSORYKOSI-AJNGGQMLSA-N APGPR Enterostatin Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 ITZMJCSORYKOSI-AJNGGQMLSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
• 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
• 102100034452 Alternative prion protein Human genes 0.000 description 1
• 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 206010002383 Angina Pectoris Diseases 0.000 description 1
• 102000018616 Apolipoproteins B Human genes 0.000 description 1
• 108010027006 Apolipoproteins B Proteins 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
• 230000007082 Aβ accumulation Effects 0.000 description 1
• 241000588832 Bordetella pertussis Species 0.000 description 1
• 101150013553 CD40 gene Proteins 0.000 description 1
• 108010009575 CD55 Antigens Proteins 0.000 description 1
• 102100022002 CD59 glycoprotein Human genes 0.000 description 1
• 241000282836 Camelus dromedarius Species 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 208000002177 Cataract Diseases 0.000 description 1
• 108010058432 Chaperonin 60 Proteins 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• 241000251204 Chimaeridae Species 0.000 description 1
• 108010032597 Cohn fraction II Proteins 0.000 description 1
• 102000000503 Collagen Type II Human genes 0.000 description 1
• 108010041390 Collagen Type II Proteins 0.000 description 1
• 108010001463 Collagen Type XVIII Proteins 0.000 description 1
• 102000047200 Collagen Type XVIII Human genes 0.000 description 1
• 108010053085 Complement Factor H Proteins 0.000 description 1
• 102000016550 Complement Factor H Human genes 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 102100031673 Corneodesmosin Human genes 0.000 description 1
• 101710139375 Corneodesmosin Proteins 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 239000003154 D dimer Substances 0.000 description 1
• NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
• AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
• ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
• 229920002079 Ellagic acid Polymers 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 108700041152 Endoplasmic Reticulum Chaperone BiP Proteins 0.000 description 1
• 102100021451 Endoplasmic reticulum chaperone BiP Human genes 0.000 description 1
• 206010014824 Endotoxic shock Diseases 0.000 description 1
• 102000010911 Enzyme Precursors Human genes 0.000 description 1
• 108010062466 Enzyme Precursors Proteins 0.000 description 1
• 239000004593 Epoxy Substances 0.000 description 1
• 206010015150 Erythema Diseases 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 241000724791 Filamentous phage Species 0.000 description 1
• 241000192125 Firmicutes Species 0.000 description 1
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
• VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
• 102000006395 Globulins Human genes 0.000 description 1
• 108010044091 Globulins Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• 102000015779 HDL Lipoproteins Human genes 0.000 description 1
• 108010010234 HDL Lipoproteins Proteins 0.000 description 1
• 101710113864 Heat shock protein 90 Proteins 0.000 description 1
• 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
• 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
• 101001082142 Homo sapiens Pentraxin-related protein PTX3 Proteins 0.000 description 1
• 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 1
• 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
• 102100022297 Integrin alpha-X Human genes 0.000 description 1
• 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
• 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 102000000588 Interleukin-2 Human genes 0.000 description 1
• 102000004890 Interleukin-8 Human genes 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• 241000581650 Ivesia Species 0.000 description 1
• 208000012659 Joint disease Diseases 0.000 description 1
• 239000007836 KH2PO4 Substances 0.000 description 1
• 241000242362 Kordia Species 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
• 101710173438 Late L2 mu core protein Proteins 0.000 description 1
• 102000004895 Lipoproteins Human genes 0.000 description 1
• 108090001030 Lipoproteins Proteins 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 102000043131 MHC class II family Human genes 0.000 description 1
• 108091054438 MHC class II family Proteins 0.000 description 1
• 238000000134 MTT assay Methods 0.000 description 1
• 231100000002 MTT assay Toxicity 0.000 description 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
• 102000050019 Membrane Cofactor Human genes 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 101710146216 Membrane cofactor protein Proteins 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 101100438619 Mus musculus Cpb2 gene Proteins 0.000 description 1
• 241000186359 Mycobacterium Species 0.000 description 1
• 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
• 102000006386 Myelin Proteins Human genes 0.000 description 1
• 108010083674 Myelin Proteins Proteins 0.000 description 1
• 241000549556 Nanos Species 0.000 description 1
• 239000012124 Opti-MEM Substances 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 208000007542 Paresis Diseases 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 102100027351 Pentraxin-related protein PTX3 Human genes 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 102000007079 Peptide Fragments Human genes 0.000 description 1
• 108010067902 Peptide Library Proteins 0.000 description 1
• 108010081690 Pertussis Toxin Proteins 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 108010071690 Prealbumin Proteins 0.000 description 1
• 206010036700 Primary immunodeficiency syndromes Diseases 0.000 description 1
• 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
• 102100038567 Properdin Human genes 0.000 description 1
• 108010005642 Properdin Proteins 0.000 description 1
• 101710188315 Protein X Proteins 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 101000640729 Rattus norvegicus Transmembrane protein 132A Proteins 0.000 description 1
• 208000035415 Reinfection Diseases 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• 206010040070 Septic Shock Diseases 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 208000006666 Shwartzman Phenomenon Diseases 0.000 description 1
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• 208000002704 Sporadic Creutzfeldt-Jakob disease Diseases 0.000 description 1
• 241000193996 Streptococcus pyogenes Species 0.000 description 1
• 241000282898 Sus scrofa Species 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 102000009190 Transthyretin Human genes 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
• COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
• 241001416177 Vicugna pacos Species 0.000 description 1
• 208000016463 Wild type ABeta2M amyloidosis Diseases 0.000 description 1
• 210000001015 abdomen Anatomy 0.000 description 1
• 230000003187 abdominal effect Effects 0.000 description 1
• 230000021736 acetylation Effects 0.000 description 1
• 238000006640 acetylation reaction Methods 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 238000010306 acid treatment Methods 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 230000004721 adaptive immunity Effects 0.000 description 1
• 230000004520 agglutination Effects 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
• 229940037003 alum Drugs 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• 229960003896 aminopterin Drugs 0.000 description 1
• 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 1
• FEWOUVRMGWFWIH-ILZZQXMPSA-N amyloid-beta polypeptide 40 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 FEWOUVRMGWFWIH-ILZZQXMPSA-N 0.000 description 1
• 230000003941 amyloidogenesis Effects 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 238000011230 antibody-based therapy Methods 0.000 description 1
• 239000003146 anticoagulant agent Substances 0.000 description 1
• 229940127219 anticoagulant drug Drugs 0.000 description 1
• 235000009697 arginine Nutrition 0.000 description 1
• 238000003149 assay kit Methods 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 239000005441 aurora Substances 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 150000001540 azides Chemical class 0.000 description 1
• 201000005008 bacterial sepsis Diseases 0.000 description 1
• 230000007321 biological mechanism Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 108010064866 biozym Proteins 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• 239000012888 bovine serum Substances 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 229940077731 carbohydrate nutrients Drugs 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 230000003833 cell viability Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 230000004700 cellular uptake Effects 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 210000000991 chicken egg Anatomy 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 238000011097 chromatography purification Methods 0.000 description 1
• 239000003593 chromogenic compound Substances 0.000 description 1
• 239000007979 citrate buffer Substances 0.000 description 1
• 108010047295 complement receptors Proteins 0.000 description 1
• 102000006834 complement receptors Human genes 0.000 description 1
• 229940125898 compound 5 Drugs 0.000 description 1
• 238000011109 contamination Methods 0.000 description 1
• 238000010924 continuous production Methods 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• 230000000593 degrading effect Effects 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 150000001993 dienes Chemical class 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
• 238000000113 differential scanning calorimetry Methods 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• 229910001873 dinitrogen Inorganic materials 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• AKHAALUPXATQSW-YZJMRIMCSA-L disodium [(2R,3R,4S,5R)-2,3,4,5-tetrahydroxy-6-oxohexyl] phosphate hydrate Chemical compound O.[Na+].[Na+].[O-]P(=O)([O-])OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O AKHAALUPXATQSW-YZJMRIMCSA-L 0.000 description 1
• VIYFPAMJCJLZKD-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate Chemical compound [Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 VIYFPAMJCJLZKD-UHFFFAOYSA-L 0.000 description 1
• KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 210000000969 egg white Anatomy 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 229960002852 ellagic acid Drugs 0.000 description 1
• 235000004132 ellagic acid Nutrition 0.000 description 1
• 238000000295 emission spectrum Methods 0.000 description 1
• 206010014599 encephalitis Diseases 0.000 description 1
• 230000012202 endocytosis Effects 0.000 description 1
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 229960001123 epoprostenol Drugs 0.000 description 1
• KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
• 150000002118 epoxides Chemical class 0.000 description 1
• 231100000321 erythema Toxicity 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
• 230000008713 feedback mechanism Effects 0.000 description 1
• 108010052295 fibrin fragment D Proteins 0.000 description 1
• 239000003527 fibrinolytic agent Substances 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 239000011888 foil Substances 0.000 description 1
• 235000019253 formic acid Nutrition 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 238000005194 fractionation Methods 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 230000013595 glycosylation Effects 0.000 description 1
• 238000006206 glycosylation reaction Methods 0.000 description 1
• 208000035474 group of disease Diseases 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 238000001631 haemodialysis Methods 0.000 description 1
• 230000023597 hemostasis Effects 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 102000057041 human TNF Human genes 0.000 description 1
• 230000002631 hypothermal effect Effects 0.000 description 1
• 230000003100 immobilizing effect Effects 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 230000009851 immunogenic response Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 230000006882 induction of apoptosis Effects 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 230000015788 innate immune response Effects 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
• 238000001155 isoelectric focusing Methods 0.000 description 1
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 210000003127 knee Anatomy 0.000 description 1
• 230000002045 lasting effect Effects 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 230000027928 long-term synaptic potentiation Effects 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
• 238000007431 microscopic evaluation Methods 0.000 description 1
• 238000000386 microscopy Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 102000035118 modified proteins Human genes 0.000 description 1
• 108091005573 modified proteins Proteins 0.000 description 1
• 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
• 235000019796 monopotassium phosphate Nutrition 0.000 description 1
• 210000005012 myelin Anatomy 0.000 description 1
• 230000001338 necrotic effect Effects 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 229910052759 nickel Inorganic materials 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 108020004707 nucleic acids Proteins 0.000 description 1
• 102000039446 nucleic acids Human genes 0.000 description 1
• QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 230000036542 oxidative stress Effects 0.000 description 1
• 238000010979 pH adjustment Methods 0.000 description 1
• 239000005022 packaging material Substances 0.000 description 1
• 230000000242 pagocytic effect Effects 0.000 description 1
• 230000036407 pain Effects 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 229940127557 pharmaceutical product Drugs 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 238000006116 polymerization reaction Methods 0.000 description 1
• 229920000193 polymethacrylate Polymers 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 201000011461 pre-eclampsia Diseases 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 230000001376 precipitating effect Effects 0.000 description 1
• 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
• 108010029690 procollagenase Proteins 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 238000002731 protein assay Methods 0.000 description 1
• 235000004252 protein component Nutrition 0.000 description 1
• 108020001580 protein domains Proteins 0.000 description 1
• 230000006916 protein interaction Effects 0.000 description 1
• 230000009145 protein modification Effects 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 230000006432 protein unfolding Effects 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 230000008085 renal dysfunction Effects 0.000 description 1
• 230000000284 resting effect Effects 0.000 description 1
• 108010051412 reteplase Proteins 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 230000028527 righting reflex Effects 0.000 description 1
• 230000000630 rising effect Effects 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Inorganic materials [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 238000011301 standard therapy Methods 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 230000000946 synaptic effect Effects 0.000 description 1
• 238000004885 tandem mass spectrometry Methods 0.000 description 1
• 239000008399 tap water Substances 0.000 description 1
• 235000020679 tap water Nutrition 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 238000005382 thermal cycling Methods 0.000 description 1
• 150000003573 thiols Chemical class 0.000 description 1
• 108010063955 thrombin receptor peptide (42-47) Proteins 0.000 description 1
• 238000000954 titration curve Methods 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 230000014616 translation Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 1
• AKYUZBFQLWFNOB-UHFFFAOYSA-K trisodium 2-hydroxypropane-1,2,3-tricarboxylate hydrochloride Chemical compound [Na+].[Na+].[Na+].Cl.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O AKYUZBFQLWFNOB-UHFFFAOYSA-K 0.000 description 1
• HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
• 229940038773 trisodium citrate Drugs 0.000 description 1
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
• 238000011870 unpaired t-test Methods 0.000 description 1
• 238000002255 vaccination Methods 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 108010047303 von Willebrand Factor Proteins 0.000 description 1
• 102100036537 von Willebrand factor Human genes 0.000 description 1
• 229960001134 von willebrand factor Drugs 0.000 description 1
• 238000013389 whole blood assay Methods 0.000 description 1
• 210000005253 yeast cell Anatomy 0.000 description 1